KRAS and non-small cell lung carcinoma: The clinical relevance of the KRAS mutational state in patients with NSCLC was assessed in one meta-analysis of 1,335 Caucasian and Asian patients who were included in 22 studies and were treated with gefitinib or erlotinib [33].